Skip to main content
News Icon

News categories: Honors & Funding

New ImmunoSensation² research group

We introduce: Dr. Hannah Scheiblich

Hannah Scheiblich and her group are investigating the role of microglia during neuroinflammation and their role in neurodegenerative diseases. Situated at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn, Scheiblich recently started her research group at the cluster of excellence.

The central nervous system (CNS) is prone to inflammation both during normal aging and during the development and progression of neurodegenerative diseases. The observed inflammatory events are mainly mediated by microglia, the brain’s specific immune cells. Microglia are highly dynamic and responsive cells that promptly respond to homeostatic changes. These changes may switch the function of microglia from housekeepers to adaptive responders executing an inflammatory response that, if persistent, causes chronic neuroinflammation and neuronal damage.

Hannah Scheiblich and her group are investigating the role of microglia during neuroinflammation and their role in neurodegenerative diseases. By combining biochemistry, cell biology, and systems biology approaches, the group aims to understand the molecular and cellular mechanisms by which neuroinflammation affects immune cell function and the progression of neurodegenerative diseases. "One of the key objectives of our lab will be to unravel the fundamental principles of microglia-neuron interaction and its role in aging and disease" Scheiblich states. The group intends to develop novel experimental approaches to reveal the molecular mechanisms through which microglia control and consolidate neuronal survival to slow the progression of neurodegenerative processes. In addition, the group is also interested in studying how microglia may play a role in other neuronal disorders.


Short biography

Hannah Scheiblich recieved her PhD from the University of Veterenary Medicine Hannover in 2015. After a research stay at the at the Medical Research Council – Toxicology Unit, at teh University of Leicester, England, Scheiblich joined the department of Neurodegenerative Diseases and Gerontopsychiatry at the University Hospital Bonn, as a postdoctoral research fellow and joined the Institute of Innate Immunity at the University Hospital Bonn in 2022. From May 2023, Hanna Scheiblich is heading a Junior Research Group at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn.


Contact

Hannah Scheiblich

Institute of Clinical Chemistry and Clinical Pharmacology

University Hospital Bonn

Venusberg Campis 1

53127 Bonn

email: hannah.scheiblich@ukbonn.de

Hannah Scheiblich
© Hannah Scheiblich / UKB

Related news

05_Bernardo_Franklin

News categories: Honors & Funding

ERC Proof of Concept Grants for UNBIAS

Prof. Bernardo Franklin from the Institute of Innate Immunity at the University Hospital Bonn has been awarded a Proof of Concept Grant by the European Research Council (ERC) as part of a program designed to help researchers translate their ideas from previous ERC projects into commercial applications. The project entiteled “Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation” (UNBIAS), aims to “wipe” the immune system’s harmful memories of inflammation. The project is awarded with a funding of €150,000, provided over a period of around one year.
View entry
Kathrin Leppek

News categories: Honors & Funding

Tuning brain cells with light

An international research team, including ImmunoSensation² member Prof. Kathrin Leppek of the University Hospital Bonn and scientists from the German Center for Neurodegenerative Diseases (DZNE), the Netherlands, and the US has been awarded a US$ 1.3 million grant by the “Human Frontier Science Program” to investigate brain immune cells and manipulate them via light irradiation. This will involve using gene transcripts (mRNAs) as molecular mediators.
View entry
Ozgun Gokce

News categories: Honors & Funding

New ImmunoSensation² research group

Neurobiologist Özgün Gökce was recently recruited to the German Center of Neurodegenerative Diseasses (DZNE) on campus of at the University Hospital Bonn. He is also a member of the Medical Faculty at Bonn University. As head of the research group "Systems Neuroscience – Cell Diversity", Gökce has been appointed as a member of ImmunoSensation2 from March 2023.
View entry

Back to the news overview